Harvard Bioscience
HBIO
HBIO
68 hedge funds and large institutions have $78.5M invested in Harvard Bioscience in 2022 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 19 increasing their positions, 31 reducing their positions, and 18 closing their positions.
New
Increased
Maintained
Reduced
Closed
more funds holding in top 10
Funds holding in top 10: →
more capital invested
Capital invested by funds: $ → $
more ownership
Funds ownership: →
less funds holding
Funds holding: →
39% less repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 31
61% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 18
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $28K
Holders
68
Holding in Top 10
2
Calls
–
Puts
$28K
Top Buyers
| 1 | +$4.08M | |
| 2 | +$1.88M | |
| 3 | +$1.75M | |
| 4 |
MIM
Meros Investment Management
Dallas,
Texas
|
+$1.11M |
| 5 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$301K |
Top Sellers
| 1 | -$801K | |
| 2 | -$797K | |
| 3 | -$782K | |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$777K |
| 5 |
MPAM
Monarch Partners Asset Management
Boston,
Massachusetts
|
-$519K |